No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
PepGen Stock Craters 35% on FDA Clinical Hold
RBC Capital Reiterates Outperform on Regenxbio, Maintains $35 Price Target
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $35
Express News | Regenxbio Inc - to Offer and Sell Shares up to $150 Million
Express News | Regenxbio Inc - on Dec 9, Co Enters Sales Agreement With Leerink Partners
Apollo Global Management, Workday to Join S&P 500
Unlock the Full List